Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label VRDN-001 study for non-responders from VRDN-001-101 and VRDN-001-301
NL-OMON60135Phase 3Completed
- Sponsor
- Viridian Therapeutics
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of veligrotug in Graves Orbitopathy (GO), sponsored by Viridian Therapeutics. Primary endpoints: Overall responder rate and Safety. Started Aug 2024; status: completed.
02
Drugs
veligrotug
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on NL-OMON60135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60135.